Basilea Ceftobiprole Saga Wages On; U.S. Development Ditched

After seven years of trying to get ceftobiprole approved in the U.S., Basilea said it would not run further clinical trials without a partner. Plans for a launch in Europe remain on track.

More from Clinical Trials

More from R&D